CERENO SCIENTIFIC AB B (4A1) - Net Assets
Based on the latest financial reports, CERENO SCIENTIFIC AB B (4A1) has net assets worth €252.47 Million EUR (≈ $295.17 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€402.67 Million ≈ $470.77 Million USD) and total liabilities (€150.20 Million ≈ $175.60 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 4A1 current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €252.47 Million |
| % of Total Assets | 62.7% |
| Annual Growth Rate | 10.38% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 15.72 |
CERENO SCIENTIFIC AB B - Net Assets Trend (2021–2025)
This chart illustrates how CERENO SCIENTIFIC AB B's net assets have evolved over time, based on quarterly financial data. Check 4A1 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for CERENO SCIENTIFIC AB B (2021–2025)
The table below shows the annual net assets of CERENO SCIENTIFIC AB B from 2021 to 2025. For live valuation and market cap data, see 4A1 market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €252.47 Million ≈ $295.17 Million |
+31.55% |
| 2024-12-31 | €191.93 Million ≈ $224.38 Million |
-11.32% |
| 2023-12-31 | €216.42 Million ≈ $253.02 Million |
+7.40% |
| 2022-12-31 | €201.51 Million ≈ $235.59 Million |
+18.49% |
| 2021-12-31 | €170.06 Million ≈ $198.82 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to CERENO SCIENTIFIC AB B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3022210200.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €252.47 Million | 100.00% |
| Total Equity | €252.47 Million | 100.00% |
CERENO SCIENTIFIC AB B Competitors by Market Cap
The table below lists competitors of CERENO SCIENTIFIC AB B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Braemar Hotel & Resorts Inc
NYSE:BHR
|
$155.90 Million |
|
Sula Vineyards Limited
NSE:SULA
|
$155.90 Million |
|
IG Petrochemicals Limited
NSE:IGPL
|
$155.91 Million |
|
i-SENS Inc
KQ:099190
|
$155.93 Million |
|
Getty Images Holdings Inc.
NYSE:GETY
|
$155.85 Million |
|
Sanara Medtech Inc
NASDAQ:SMTI
|
$155.84 Million |
|
Westwood Holdings Group Inc
NYSE:WHG
|
$155.79 Million |
|
Petronor E&P Ltd
OL:PNOR
|
$155.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CERENO SCIENTIFIC AB B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 191,926,446 to 252,471,538, a change of 60,545,092 (31.5%).
- Net loss of 117,754,773 reduced equity.
- New share issuances of 104,337,498 increased equity.
- Other factors increased equity by 73,962,367.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-117.75 Million | -46.64% |
| Share Issuances | €104.34 Million | +41.33% |
| Other Changes | €73.96 Million | +29.3% |
| Total Change | €- | 31.55% |
Book Value vs Market Value Analysis
This analysis compares CERENO SCIENTIFIC AB B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.53x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.27x to 0.53x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €1.62 | €0.43 | x |
| 2022-12-31 | €1.47 | €0.43 | x |
| 2023-12-31 | €0.93 | €0.43 | x |
| 2024-12-31 | €0.68 | €0.43 | x |
| 2025-12-31 | €0.81 | €0.43 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CERENO SCIENTIFIC AB B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -46.64%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.59x
- Recent ROE (-46.64%) is below the historical average (-28.80%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -9.56% | 0.00% | 0.00x | 1.06x | €-33.26 Million |
| 2022 | -13.72% | 0.00% | 0.00x | 1.07x | €-47.81 Million |
| 2023 | -22.23% | 0.00% | 0.00x | 1.32x | €-69.75 Million |
| 2024 | -51.86% | 0.00% | 0.00x | 2.16x | €-118.72 Million |
| 2025 | -46.64% | 0.00% | 0.00x | 1.59x | €-143.00 Million |
Industry Comparison
This section compares CERENO SCIENTIFIC AB B's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $7,556,298,297
- Average return on equity (ROE) among peers: -31.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| CERENO SCIENTIFIC AB B (4A1) | €252.47 Million | -9.56% | 0.59x | $155.87 Million |
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | $61.84 Billion | 5.45% | 0.94x | $1.16 Billion |
| PEPTONIC MEDICAL (28L) | $47.09 Million | -78.27% | 0.82x | $4.14 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.95 Billion | 11.12% | 0.39x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $4.89 Million | -63.10% | 0.49x | $97.35K |
| MAPLE LEAF GREEN WORLD (4HV0) | $-9.91 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $17.35 Million | -23.30% | 0.22x | $9.05 Million |
| EQL PHARMA AB (7JK) | $154.75 Million | 19.98% | 0.85x | $62.07 Million |
About CERENO SCIENTIFIC AB B
Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden and internationally. The company's lead drug candidate is CS1, a product candidate that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an … Read more